Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

You may be eligible if

• Histologically confirmed anaplastic large cell lymphoma
• CD30-positive disease
• Must be in first or second relapse
• Measurable disease
• No CNS disease
• Karnofsky performance status (PS) 60-100% (\> 16 years of age) OR Lansky PS 60-100% (≤ 16 years of age)
• Absolute neutrophil count ≥ 1,000/mm³
• Platelet count ≥ 100,000/mm³ (transfusion independent)
• * Platelet count ≥ 20,000/mm³ if bone marrow involvement (platelet transfusions allowed)
• Hemoglobin ≥ 8.0 g/dL (RBC transfusion independent, unless bone marrow involvement)
• Creatinine adjusted according to age as follows:
• * No greater than 0.4 mg/dL (≤ 5 months)
• * No greater than 0.5 mg/dL (6 months-11 months)
• * No greater than 0.6 mg/dL (1 year-23 months)
• * No greater than 0.8 mg/dL (2 years-5 years)
• * No greater than 1.0 mg/dL (6 years-9 years)
• * No greater than 1.2 mg/dL (10 years-12 years)
• * No greater than 1.4 mg/dL (13 years and over \[female\])
• * No greater than 1.5 mg/dL (13 years to 15 years \[male\])
• * No greater than 1.7 mg/dL (16 years and over \[male\])
• Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min
• Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• ALT \< 3 times ULN
• Albumin ≥ 2 g/dL
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for ≥ 3 months after completion of study treatment
• No evidence of graft-vs-host disease
• No documented active infection requiring antibiotics
• No isolated bone recurrence
• Recovered from prior therapy
• At least 3 months since prior monoclonal antibody therapy
• At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)
• At least 7 days since prior hematopoietic growth factor therapy
• At least 3 months since prior biologic (antineoplastic) agents
• At least 2 weeks since prior local palliative radiotherapy (small port)
• At least 3 months since prior total-body irradiation, craniospinal radiotherapy, or radiotherapy to ≥ 50% of the pelvis
• At least 6 weeks since other prior substantial bone marrow irradiation
• At least 2 months since prior stem cell transplantation or rescue
• No prior monoclonal antibody SGN-30
• Concurrent steroids allowed provided dose has been stable or decreasing for the past 7 days
• No concurrent immunosuppressive agents
• No concurrent dexamethasone as an antiemetic
• No other concurrent investigational drug or anticancer agents, including chemotherapy, radiotherapy, immunotherapy, or biological therapy